Understanding The Biology and Potential Drug Targeting of Cullin-5

Target Name: CUL5

NCBI ID: G8065

CUL5

Understanding The Biology and Potential Drug Targeting of Cullin-5

Cullin-5 (Cul5) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the calcium-mobilizing receptor (CaM) family, which is a subclass of G protein-coupled receptors (GPCRs) that play a crucial role in cellular signaling. One of the unique features of CaM receptors is their ability to activate calcium ions, which can then trigger a variety of downstream signaling pathways.

Cullin-5 has been identified as a potential drug target due to its involvement in several important cellular processes, including pancreatic cancer, obesity, and neurodegenerative diseases. In this article, we will discuss the biology of Cullin-5, its potential drug targeting implications, and the research being conducted to understand its role in these disease processes.

biology of Cullin-5

Cullin-5 was first identified in 2004 as a gene that encodes a protein that was expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. The protein encoded by the Cullin-5 gene is a 21-kDa protein that contains 10 unique amino acid residues.

Expression of Cullin-5 has been shown to be regulated by several different factors, including calcium ions, tyrosine, and insulin. For example, studies have shown that Cullin-5 is highly expressed in pancreatic cancer cells, and that it is involved in the regulation of pancreatic cancer cell growth and survival.

In addition to its role in cancer, Cullin-5 has also been shown to be involved in several other important cellular processes. For example, it has been shown to play a role in the regulation of insulin sensitivity and glucose metabolism, as well as in the development and progression of neurodegenerative diseases.

Potential drug targeting implications

Cullin-5's involvement in several important cellular processes makes it an attractive target for drug development. One of the potential benefits of targeting Cullin-5 is its ability to disrupt the signaling pathways that are driven by this protein, leading to a variety of cellular and physiological changes.

For example, research has shown that Cullin-5 is involved in the regulation of pancreatic cancer cell growth and survival, and that targeting this protein may have implications for the treatment of pancreatic cancer. Additionally, Cullin-5 has been shown to be involved in the regulation of insulin sensitivity and glucose metabolism, which makes it a potential target for the treatment of obesity and other metabolic disorders.

Another potential benefit of targeting Cullin-5 is its role in the regulation of neurodegenerative diseases. Studies have shown that Cullin-5 is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, targeting this protein may have implications for the treatment of these diseases.

Research being conducted

Research is being conducted to understand the role of Cullin-5 in several important cellular processes, including cancer, obesity, and neurodegenerative diseases. One of the main areas of focus is the study of Cullin-5's role in the regulation of pancreatic cancer cell growth and survival.

For example, researchers have shown that Cullin-5 is involved in the regulation of pancreatic cancer cell growth and that targeting this protein may have implications for the treatment of pancreatic cancer. Additionally, researchers have shown that Cullin-5 is involved in the regulation of insulin sensitivity and glucose metabolism, which makes it a potential target for the treatment of obesity and other metabolic disorders.

Another area of focus is the study of Cullin-5's role in the regulation

Protein Name: Cullin 5

Functions: Core component of multiple SCF-like ECS (Elongin-Cullin 2/5-SOCS-box protein) E3 ubiquitin-protein ligase complexes, which mediate the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:11384984, PubMed:15601820). As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme (PubMed:11384984, PubMed:15601820). The functional specificity of the E3 ubiquitin-protein ligase complex depends on the variable substrate recognition component (PubMed:11384984, PubMed:15601820). ECS(SOCS1) seems to direct ubiquitination of JAK2 (PubMed:11384984). ECS(KLHDC1) complex is part of the DesCEND (destruction via C-end degrons) pathway and mediates ubiquitination and degradation of truncated SELENOS selenoprotein produced by failed UGA/Sec decoding, which ends with a glycine (PubMed:32200094). As part of a multisubunit complex composed of elongin BC complex (ELOB and ELOC), elongin A/ELOA, RBX1 and CUL5; polyubiquitinates monoubiquitinated POLR2A (PubMed:19920177). May form a cell surface vasopressin receptor (PubMed:9037604)

The "CUL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CUL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets